ABSTRACT: Introduction: Paraneoplastic autoantibody screening of 150,000 patient sera by tissue-based immunofluorescence incidentally revealed 170 with unsuspected signal recognition particle (SRP) immunoglobulin G (IgG), which is a recognized biomarker of autoimmune myopathy. Of the 77 patients with available information, 54 had myopathy. We describe the clinical/laboratory associations. Methods: Distinctive cytoplasm-binding IgG (mouse tissue substrate) prompted western blot, enzyme-linked immunoassay, and immunoprecipitation analyses. Available histories were reviewed. Results: The immunostaining pattern resembled rough endoplasmic reticulum, and mimicked Purkinje-cell cytoplasmic antibody type 1 IgG/anti-Yo. Immunoblotting revealed ribonucleoprotein reactivity. Recombinant antigens confirmed the following: SRP54 IgG specificity alone (17); SRP72 IgG specificity alone (3); both (32); or neither (2). Coexisting neural autoantibodies were identified in 28% (low titer). Electromyography revealed myopathy with fibrillation potentials; 78% of biopsies had active necrotizing myopathy with minimal inflammation, and 17% had inflammatory myopathy. Immunotherapy responsiveness was typically slow and incomplete, and relapses were frequent on withdrawal. Histologically confirmed cancers (17%) were primarily breast and hematologic, with some others. Conclusions: Autoimmune necrotizing SRP myopathy, both idiopathic and paraneoplastic, is underdiagnosed in neurological practice. Serological screening aids early diagnosis. Cancer surveillance and appropriate immunosuppressant therapy may improve outcome. 53: 925-932, 2016 
aminoacyl (histidyl)-tRNA synthetase autoantibody], is reported in 25%-30% of patients with dermatomyositis. IgGs specific for signal recognition particle (SRP) components (54-kDa, 72-kDa, and 7-SL RNA) have been reported with inflammatory and non-inflammatory autoimmune myopathies. [2] [3] [4] [5] [6] An ill-defined cancer association is recognized for autoimmune myopathies, particularly dermatomyositis. 7 Here we report fortuitous detection of unsuspected SRP-specific immunoglobulin G (IgG) in a neurological patient population evaluated serologically for paraneoplastic autoantibodies by a standardized tissue-based immunofluorescence screening assay.
METHODS
The study was approved by the institutional review board at the Mayo Clinic. A distinctive SRPlike IgG-binding pattern was noted in 170 patients evaluated serologically for possible paraneoplastic neurological autoimmunity by routine service immunofluorescence in the Mayo Clinic Neuroimmunology Laboratory. In all cases, testing had been requested by a consulting neurologist, generally not a neuromuscular subspecialist. Of the 170 patients, clinical information was available for 77 (27 evaluated at the Mayo Clinic; limited information was obtained for 50 of 143 non-Mayo Clinic patients through consultation with the evaluating physicians). Fifty-four patients (70%; 20 of whom were seen at the Mayo Clinic) had predominant subacute myopathy (progressive proximal weakness, elevated creatine kinase, and electromyographic evidence of short-duration, low-amplitude motor unit potentials with early recruitment and fibrillation potentials). The remaining 23 patients (7 Mayo Clinic) presented with other neurological manifestations and lacked myopathy. They will be the subject of a subsequent report.
Immunofluorescence Screening. A composite substrate of cryosectioned mouse cerebellum/midbrain/hippocampus, gut, and kidney tissues (4 mm thick) was prefixed for 10 minutes in 10% formalin. Sera were applied to the substrate after absorption at 1:240 dilution with bovine liver powder in phosphate-buffered saline (PBS) containing 1% Patient Antibody Purification. Mouse pancreatic lysate proteins were separated by electrophoresis and transblotted to nitrocellulose. Bound antigenic protein was located by Western blot staining of excised vertical edge strips. Horizontal strips bearing the antigens of interest and a control horizontal strip lacking the antigen of interest were exposed to patient sera (1:400 dilution, 2 hours). After washing the strips to remove non-specifically bound antibody [6 times in 50 mM Tris-HCl (pH 7.6), containing 300 mM NaCl], bound IgG was eluted in 0.1 M acetic acid, neutralized with 2 M Tris, dialyzed 16 hours against PBS with sodium azide 0.02%, and concentrated by Amicon Ultra tube centrifugation (final volume < 100 ml). This IgG was applied to the composite mouse tissue substrate to evaluate its immunofluorescence staining pattern. SRP-Subunit-Specific Antibody Assays. SRP54-IgG reactivity was tested by enzyme-linked immunoassay (ELISA). Sera, diluted in doubling steps from 1:60 in PBS containing 10% normal goat serum, were applied to Immulon II plates coated with recombinant SRP54 protein (0.5 mg/ml). After holding for 2 hours at 37 8C, the wells were washed 3 times with PBS containing sodium azide (0.02%) and goat serum (2%), then alkaline phosphatase-conjugated goat IgG specific for human IgG (Rockland Immunochemicals, Inc., Gilbertsville, Pennsylvania) was added. After 1 hour at 37 8C, wells were washed, substrate was added (p-nitrophenyl phosphate at 1 mg/ml in diethanolamine buffer, pH 9.8), and the plates were held for 1 hour at 37 8C. The reaction product was measured photometrically (wavelength 405 nm; ELx800; BioTek Instruments, Inc.). Values exceeding 150% of the mean optical density yielded by corresponding dilutions of 4 healthy control human sera were considered positive. Positive sera were retested and titrated further as necessary to determine the endpoint dilution. Results were expressed as titer (i.e., reciprocal of the final positive dilution).
SRP72 IgG reactivity was tested by immunoprecipitation assay. Patient sera (30 ml) were added to 100 ml of sonicated transfected cell lysate containing 15,000 GFP counts (in 2% Triton X-100, 10 mM Tris, 1 mM ethylene-diamine tetraacetic acid, 700 mM NaCl, 0.02% sodium azide; clarified by ultracentrifugation). After shaking at 4 8C overnight, immune complexes were captured by adding 30 ml of recombinant Protein G-Sepharose 4B (Novex/Invitrogen, Grand Island, New York), pelleted centrifugally after 2 hours (2,000 3 g, 2 minutes, 4 8C), washed 3 times with 1 ml of lysis buffer, and resuspended in 200 ml of lysis buffer. Precipitated GFP SRP72 in 100-ml aliquot was measured spectrophotometrically in a black flat-bottom plate (Tecan GENios Pro). Results were expressed in nanomoles per liter by reference to a GFP standard (Promega).
Other Autoantibody Tests. All patient sera were tested for neural-specific IgG autoantibodies according to comprehensive evaluation standardized in the Mayo Clinic Neuroimmunology Laboratory: mouse tissue-based immunofluorescence to screen for neuronal and glial nuclear, cytoplasmic, and synaptic antibodies; radioimmunoprecipitation for cation channel antibodies and glutamic acid decarboxylase 65 (GAD65) antibody; and ELISA for skeletal muscle striational antibodies. 9 Service testing for thyroid and antinuclear antibodies was performed on all Mayo Clinic patient sera in the Mayo Clinic Immunology Laboratory.
Statistical Analysis. Either Student t-test, Fisher exact test, Wilcoxon rank sum test, or Mann-Whitney U-test was employed as appropriate.
RESULTS
Immunohistochemical Characteristics. Between July 1, 2007 and June 30, 2012, 150,000 patient sera were tested for paraneoplastic IgG autoantibodies on a service basis using a standardized composite tissue-based immunofluorescence screening assay.
In 170 sera we noted an autoantibody pattern not previously described and not yielded by thousands of healthy and disease control sera. Although not organ-specific, this IgG bound prominently to cytoplasm of cerebellar cortical neurons (Purkinje, molecular, and Golgi) and resembled PCA-1 IgG (anti-Yo; Fig. 1A) , 10 except for also binding to cytoplasm of cerebellar granular neurons ("chickenwire pattern"; Fig. 1B ). Like PCA-1 IgG, the novel IgG bound to all large neurons, including myenteric ganglionic neurons (Fig. 1C, arrowhead) ; it also bound distinctively to hippocampal neurons (Fig. 1D ). This IgG bound prominently to certain non-neural elements, including cytoplasm of proximal gastric mucosal epithelial cells (Fig. 1C,  arrow) , choroid epithelium (Fig. 1E) , and renal tubules (cortical more than medullary; Fig. 1F ). The resemblance of the cytoplasmic staining in large neurons of the cerebellar cortex to PCA-1 immunoreactivity suggested the autoantigen may reside in endoplasmic reticulum, as this laboratory demonstrated with immunoelectron microscopy for the PCA-1 antigen. 10 Sera from the 54 patients presenting with myopathy were further analyzed.
Western Blot Characteristics. Detailed testing of the first 25 sera revealed that IgG in 12 bound to native microsomal proteins of 54-kDa (6) or 72-kDa (10) molecular size, consistent with SRP54 and SRP72 subunits; 4 sera were dual-reactive ( Fig. 2A shows 2 review, 14 showed predominantly necrotizing myopathy (scattered necrotic fibers and regenerating fibers) with minimal or no lymphocytic infiltration, and 3 showed an inflammatory myopathy with endomysial and perimysial lymphocytic inflammatory reaction. The GVHD patient's biopsy showed predominantly perifascicular myofiber atrophy, multifocal capillary depletion, and membrane attack complex deposition in intramuscular capillaries, but no necrosis, regeneration, or inflammation, suggestive of GVHD-associated myopathy.
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No biopsied tissue had autoaggressive inflammatory mononuclear cells attacking healthy muscle fibers. Although scant muscle fiber vacuoles were present in 2 biopsies, the pattern of weakness (proximal, symmetrical), favorable immunotherapy responses, and lack of autoaggressive inflammation and congophilic inclusions argued against the diagnosis of inclusion-body myositis. Except for the GVHD patient, no patient had pathological findings of dermatomyositis, necrotizing vasculitis, or granulomatous myopathy.
Evidence of Coexisting Autoimmunity. Coexisting autoimmune conditions were reported for 17 of 46 (37%) patients with a documented autoimmune history (Raynaud phenomenon 8, hypothyroidism 3, connective tissue disease 3, pernicious anemia 2, Sj€ ogren syndrome 2, alopecia areata 2, rheumatoid arthritis 1, and diabetes mellitus 1). Remote sarcoidosis with liver involvement was reported in 1 patient.
Coexisting neural autoantibodies, identified in 15 of the 54 patients (28%), were specific for voltagegated potassium channel-complex, N-type voltagegated calcium channel, ganglionic acetylcholine receptor, GAD65, and sarcomere (striational; see Table 1 ). PCA-1 IgG was negative in all patients. Only Mayo Clinic patients (20) had available data for non-neural autoantibodies. Fifty percent of patients had non-organ-specific autoantibodies [antinuclear antibody (ANA) > > ribonucleoprotein, Smith (Sm), double-stranded DNA, anti-phospholipid antibody, or rheumatoid factor]; 40% had thyroid autoantibodies (Table 1) . No patient was positive for Jo-1 antibodies.
Oncological Findings or History. Malignant neoplasms were documented in 9 patients, either contemporaneously or in past history (breast adenocarcinoma 3, lymphoma 2, acute myeloid leukemia 1, colon adenocarcinoma 1, renal cell carcinoma 1, thyroid papillary carcinoma 1, prostate carcinoma 1). The patient with acute myeloid leukemia was diagnosed in the course of therapy for initially diagnosed breast carcinoma. In 3 patients, the diagnosis of myopathy preceded cancer discovery (mean interval 5 months), and in 4 patients myopathy diagnosis followed cancer discovery (mean interval 50 months); the timing of cancer discovery was unknown for 2 patients.
Treatment Responses. Clinical information 6 months or more posttreatment was available for 31 patients (57%). All received an initial trial of highdose corticosteroids. Overall, 26 patients (84%) improved; 81% of responders required additional immunotherapy (usually intravenous immune globulin and methotrexate or mycophenolate mofetil). The median time elapsed from symptom onset to treatment was 6 (range 1-36) months. Therapy in 3 responders commenced at 24, 30, and 36 months after symptom onset. Recovery was typically slow. Most patients had improved after 18 months of therapy, but not to baseline. More than 70% of responders relapsed on withdrawal of immunosuppression, necessitating extended therapy. One patient who deteriorated significantly during relapse failed to regain lost function despite rapid reintroduction of therapy.
Prospective
Analysis of SRP IgG Detection
Frequency. Between January 1 and December 31, 2012, we detected SRP IgG in 26 patient sera (0.06%) among the 40,400 evaluated by service immunofluorescence assay for neural autoantibodies. In the same period, we detected (and confirmed by native Western blot assay) PCA-1 (antiYo) in 27 patient sera (0.07%).
DISCUSSION
The method of patient ascertainment distinguishes our study of SRP autoantibody associations from any previous report. Earlier studies have selectively tested for SRP autoantibody in patients with rheumatologic or muscle disease (inflammatory or otherwise). SRP IgG was not suspected in the patients in our study, but it was identified incidentally through service screening for neural-restricted paraneoplastic IgG autoantibodies by tissue-based immunofluorescence assay. The patients presented with diverse subacute neurological problems, usually dominated by profound weakness. Because the ordering neurologist's early consideration was a paraneoplastic etiology, serological testing for "myositis-pertinent" autoantibodies had not been considered in most cases. In some patients, previous SRP antibody testing by a commercial laboratory had been reported to be negative. The unanticipated serological finding correlated in 70% of patients with a final diagnosis of myopathy (particularly necrotizing autoimmune myopathy). Subsequent testing with recombinant antigens revealed IgGs specific for the 54-or 72-kDa subunits of SRP in 96% of patients. The final clinical diagnosis of necrotizing autoimmune myopathy in the 9% of patients negative for SRP54 IgG (4% lacked evidence for either SRP54 IgG or SRP72 IgG) suggests another SRP component as antigen in some, or greater sensitivity of the tissuebased immunofluorescence assay than ELISA or immunoprecipitation for detection of SRP antibody. The latter possibility awaits prospective investigation. Typical of necrotizing autoimmune myopathy, creatine kinase was elevated, and electromyography supported the diagnosis of an active proximal-predominant myopathy in all patients. 4 In 75% of patients, muscle biopsies were found to be consistent with necrotizing myopathy, with minimal or no inflammation. 12 Evidence of autoaggressive inflammation was lacking in the 17% of patients who had an inflammatory myopathy. It is noteworthy that 13% of our cohort had coexisting neurological problems (peripheral neuropathy, encephalopathy, or dysautonomia). This suggests that neurological involvement associated with SRP IgG may be more widespread than previously recognized.
Autoantibodies reactive with the 54-kDa component of the hexameric SRP, 2 and subsequently antibodies reactive with the 7-SL RNA component, 5 were described initially as a marker of polymyositis. Because early diagnostic criteria for inflammatory muscle disorders did not require a histological diagnosis nor did they recognize autoimmune necrotizing myopathy as a distinct entity, 13 early serological reports may have misclassified patients with necrotizing myopathy as severe polymyositis cases. The SRP54 IgG association with autoimmune necrotizing myopathy has been recognized increasingly in the past 9 years. SRP72-reactive IgG has also been reported. 1 We emphasize the value of serological testing as a diagnostic aid for necrotizing autoimmune myopathy, because it is not uncommon for lack of evident inflammation in biopsied muscle to dissuade a non-neuromuscular specialist neurologist from entertaining the diagnosis of immune-mediated myopathy. A recently recognized unrelated IgG autoantibody, specific for 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR, the rate-controlling enzyme of the cholesterol-biosynthesizing mevalonate pathway), is a second biomarker of a histopathologically indistinguishable and similarly immunotherapyresponsive autoimmune necrotizing myopathy. 14 Although initially recognized as statin therapy related, a majority of HMGCR IgG-positive cases are idiopathic.
14 Additional examples of the particular diagnostic value of autoimmune serology include patients who have slow progression or are untreated and have longstanding weakness. As in 1 of our patients, SRP myopathy may be misdiagnosed as muscular dystrophy. 15 The myopathy cohort we have described is similar overall in demographic and clinical characteristics to previously studied cohorts with SRP IgG-associated myopathies. 1, 5 Patient ascertainment bias through physician-ordered paraneoplastic serological screening plausibly accounts for the higher cancer frequency documented here than previously reported for patients with SRP IgG (17% vs. 10%). 4, 16 This suggestion is supported by the reported 18% frequency of cancer history in a control group of adult Mayo Clinic neurology patients for whom service paraneoplastic serological evaluation yielded no positive findings. 17 Breast adenocarcinoma and hematologic malignancy were most common, but we also encountered carcinomas of colon, thyroid, kidney, and prostate. Limited follow-up information for 3 patients (smokers with pulmonary radiological abnormalities noted) suggested a cancer frequency exceeding 17%.
The beneficial responses observed in recipients of aggressive and sustained immunotherapy emphasize the importance for neurologists to be aware of the entity of autoimmune necrotizing myopathy. No standardized treatment has been established, but, based on our continuing experience and the work of others, 14, 18 we currently recommend at least 3 months of combined therapy with intravenous immune globulin (IVIg), corticosteroids, and a steroid-sparing immunosuppressant, followed by long-term treatment with the steroidsparing agent. However, treatment must be individualized. Tapering of immunosuppressant drugs should be done cautiously to avoid relapse. IVIg is beneficial early in the disease course to manage relapses or when corticosteroids are contraindicated. The majority of patients will require longterm immunosuppression. Acknowledging our patient ascertainment bias, we nevertheless recommend that patients with autoimmune necrotizing SRP myopathy be screened for occult malignancy, guided by risk factors and past and family history (mammogram, prostate evaluation, whole-body positron emission tomography-computed tomography, and upper and lower gastrointestinal endoscopy).
In conclusion, autoimmune SRP myopathy is a severe but treatable entity that appears to be underdiagnosed in neurological practice. At least 1 in every 6 of these patients has an associated malignancy. The novel SRP IgG immunostaining pattern we have described enables serological detection of at least 2 SRP subunit-specific autoantibodies (SRP54 and SRP72). The diagnosis of necrotizing autoimmune myopathy may be challenging because the finding of minimal or no evidence of inflammation on muscle biopsy may point non-subspecialist neurologists away from an immune-mediated etiology and dissuade them from implementation of immune-modulating therapy. Improvement is usually slow and requires long-term immunotherapy with more than a single agent. Relapses are frequent when immunotherapy is reduced. Early treatment is ideal.
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